Compare VSAT & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VSAT | MIRM |
|---|---|---|
| Founded | 1986 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.4B |
| IPO Year | 1996 | 2019 |
| Metric | VSAT | MIRM |
|---|---|---|
| Price | $46.59 | $88.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | $46.20 | ★ $114.67 |
| AVG Volume (30 Days) | ★ 1.4M | 806.2K |
| Earning Date | 02-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 50.88 | ★ 74.59 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $19,138,000.00 |
| Revenue This Year | $5.34 | $26.22 |
| Revenue Next Year | $3.59 | $21.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.36 | $36.88 |
| 52 Week High | $52.70 | $109.28 |
| Indicator | VSAT | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 48.64 | 43.42 |
| Support Level | $41.76 | $85.76 |
| Resistance Level | $50.53 | $96.65 |
| Average True Range (ATR) | 3.20 | 3.59 |
| MACD | -0.18 | -0.15 |
| Stochastic Oscillator | 21.04 | 29.33 |
Viasat Inc provides bandwidth technologies and services in three segments: communication services and defense and advanced technologies. The communication services segment provides a wide range of broadband and narrowband communications solutions across government and commercial mobility markets, as well as for residential and enterprise fixed broadband customers: and the defense and advanced technologies segment develops and offers a diverse array of resilient, vertically integrated solutions to government and commercial customers, leveraging core technical competencies in encryption, cyber security, tactical gateways, modems and waveforms. A large majority of the firm's revenue is generated from communication services segment.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.